Multicenter evaluation of pramiracetam for the treatment of memory impairment of probable vascular origin

This multicenter, open, noncomparative study involved 104 elderly patients with cognitive impairment of probable vascular origin. On the basis of Mini- Mental State Examination score, patients were further characterized as having mild or moderate memory impairment. Pramiracetam was administered orally twice a day at 600 mg for 3 months. Patients were evaluated before treatment and after 30, 60, and 90 days by means of the Mini-Mental State, Information- Memory-Concentration, Figures Repetition, and Rey's 15 Words tests. Pramiracetam proved to be safe and clinically effective in improving mental deterioration, with an order of magnitude closely related to the severity of the memory disorder.